The National Pharmaceutical Pricing Authority (NPPA) on November 02, 2026, issued a notification regarding the revised MRP of Non-Scheduled Anti-Cancer Drugs.
The following has been stated: -
•The National Pharmaceutical Pricing Authority (NPPA) has issued revised Maximum Retail Prices (MRP) for various non-scheduled anti-cancer drugs, based on data received from pharmaceutical companies up to November 02, 2026.
•The revised prices cover multiple medicines, including Abiraterone, Acalabrutinib, Afatinib, Bevacizumab, and other anti-cancer drugs across different strengths, brands and manufacturers.
•The revised MRPs shall be effective from November 09, 2026. Pharmaceutical companies and manufacturers concerned shall comply with the revised pricing.
The detailed notification is given in the document below.
